Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 6/20 | 0.51 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.51 |
| ▸ | IGF1R | P08069 | 4/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251370 | 1.00 | TGFBR1 (0.53) | TGFBR1PIM1PIM2IGF1RPIM3 | |
| SCHEMBL4257918 | 0.90 | PIM1 (0.49) | TGFBR1PIM1PIM2IGF1RPIM3 | |
| SCHEMBL4254082 | 0.86 | RAB9A (0.51) | PIM1PIM2IGF1RPIM3PIK3CG | |
| SCHEMBL4254079 | 0.86 | RAB9A (0.51) | PIM1PIM2IGF1RPIM3PIK3CG | |
| SCHEMBL4255964 | 0.85 | PIK3CG (0.54) | PIM1PIM2PIM3PIK3CGPIK3CA | |
| SCHEMBL4255970 | 0.85 | PIK3CG (0.54) | PIM1PIM2PIM3PIK3CGPIK3CA | |
| SCHEMBL4260636 | 0.84 | PIK3CG (0.47) | PIM1PIM2IGF1RPIM3PIK3CG | |
| SCHEMBL4257913 | 0.84 | PIK3CG (0.47) | PIM1PIM2IGF1RPIM3PIK3CG | |
| SCHEMBL4250642 | 0.83 | PIK3CG (0.53) | PIM1PIM2IGF1RPIM3PIK3CG | |
| SCHEMBL4250648 | 0.83 | PIK3CG (0.53) | PIM1PIM2IGF1RPIM3PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | claimed |
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2008014219-A2 | THIOZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PI4KA, PIP4K2A | TGFBR1 444/4885PIM1 103/4885PIM2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.